IMVT

Immunovant, Inc.

A clinical-stage biopharmaceutical company developing experimental antibody medicines for autoimmune diseases, where the body's own defenses attack healthy tissue. Its drug candidates, like batoclimab, work by lowering the harmful antibodies that drive these conditions. Immunovant was founded in 2018 within the Roivant Sciences family and went public in 2019 through a merger. Its name blends "immuno," for immunology, with the "-vant" suffix that Roivant gives all its specialized subsidiaries.

CUSIP: 45258J102HealthcareUS1 holder

Ownership Activity Financials Filings

IMVT

IMVT

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Other Events

Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Regulation FD Disclosure